Regulatory Post-Marketing Surveillance
Showing 1 - 25 of >10,000
Xolair® for Chronic Rhinosinusitis With Nasal Polyps
Recruiting
- Chronic Rhinosinusitis With Nasal Polyps
- Xolair
-
Bundang Gu, Gyeonggi Do, Korea, Republic ofNovartis Investigative Site
Jan 19, 2023
Diphtheria, Tetanus, Pertussis Trial in Seoul (TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and
Completed
- Diphtheria
- +3 more
- TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio
-
Seoul, Korea, Republic of(unnamed)
Mar 15, 2022
'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
Recruiting
- Ovarian Cancer
- +3 more
-
Busan, Korea, Republic of
- +17 more
Jan 9, 2023
Lucentis® in Patients With Retinopathy of Prematurity
Not yet recruiting
- Retinopathy of Prematurity
- Lucentis
- (no location specified)
Jun 28, 2022
ELIQUIS Regulatory Post-Marketing Surveillance In Clinical
Completed
- Venous Thromboembolism
-
Shinjuku-ku, Tokyo, JapanLocal Institution
Feb 3, 2022
Vahelva Respimat Regulatory Post-marketing Surveillance in
Completed
- Pulmonary Disease, Chronic Obstructive
- Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
-
One Or Multiple Sites, Korea, Republic ofChonnam National University Hospital
Feb 28, 2022
A 24-week rPMS Study in Real-world Setting for Enerzair
Recruiting
- Asthma
- Enerzair 150/50/80 μg
- Enerzair 150/50/160 μg
-
Suncheon, Jeollanam-do, Korea, Republic ofNovartis Investigative Site
Jun 13, 2022
Regulatory Post-Marketing Surveillance Study for Brolucizumab
Recruiting
- Neovascular Age-related Macular Degeneration
- brolucizumab
-
Daegu, Dalseo Gu, Korea, Republic of
- +26 more
Jun 21, 2022
A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS
Recruiting
- Asthma
- Atectura inhalation capsule (150/80ug)
- +2 more
-
Gwangju, Korea, Republic ofNovartis Investigative Site
Sep 5, 2022
(rPMS) Study of Xultophy® to Evaluate Safety and Effectiveness
Enrolling by invitation
- Diabetes Mellitus, Type 2
- Xultophy® (insulin degludec/liraglutide)
-
Daejeon, Cheongsa-ro, Seo-gu, Korea, Republic of
- +9 more
Mar 21, 2022
(PMS) in Korean Patients With Type 2 Diabetes Mellitus
Recruiting
- Diabetes Mellitus, Type 2
-
Cheonan-si, Cheonan-si, Chungcheongnam-do, Korea, Republic of
- +2 more
Jul 26, 2022
(rPMS) Study of Ryzodeg® FlexTouch® to Evaluate Safety and
Completed
- Diabetes
- +2 more
- Insulin degludec /insulin aspart
-
Busan, Korea, Republic of
- +26 more
Nov 9, 2021
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
Completed
- Colorectal Neoplasms
- Regorafenib (Stivarga,BAY73-4506)
-
Multiple Locations, Korea, Republic of(unnamed)
Apr 26, 2020
Data of Intravitreal Aflibercept Injection in Patients of Wet
Completed
- Wet Age-related Macular Degeneration
- Aflibercept (Eylea, BAY86-5321)
-
Multiple Locations, IndiaMany Locations
Feb 2, 2023
Saphir Stem in Primary Hip Surgery
Recruiting
- Arthropathy of Hip
- hip arthroplasty with prosthesis
-
Toulouse, FranceHopital Ducuing
Dec 12, 2022
CTAG Dissection/Trauma Post Marketing Surveillance Japan
Completed
- Thoracic Aortic Aneurysm
- +2 more
- Conformable GORE® TAG® Thoracic Endoprosthesis
- (no location specified)
Jan 11, 2023
Korean Type 2 Diabetes Mellitus
Completed
- Diabetes Mellitus, Type 2
- JARDIANCE 10mg
- JARDIANCE 25mg
-
Multiple Locations, Korea, Republic of(unnamed)
Apr 15, 2021
Assess the Safety of Fedratinib in Korean Myelofibrosis
Recruiting
- Primary Myelofibrosis
- +2 more
-
Seoul, Korea, Republic ofBristol-Myers Squibb YH
Oct 3, 2023
Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases
Active, not recruiting
- Lung Diseases, Interstitial
-
Tokyo, JapanNippon Boehringer Ingelheim Co., Ltd.
Jan 9, 2023
Jardiance® Post Marketing Surveillance in Korean Chronic Heart
Recruiting
- Heart Failure
-
Anyang-si, Gyeonggi-do, Korea, Republic of
- +19 more
Jan 10, 2023